Aclaris Therapeutics (ACRS) CEO Neal Walker on Q4 2018 Results - Earnings Call Transcript

Aclaris Therapeutics (NASDAQ:ACRS) Q4 2018 Earnings Conference Call March 18, 2019 8:00 AM ET

Company Participants

Kamil Ali-Jackson - Co-Founder and Chief Legal Officer
Neal Walker - Co-Founder Chief Executive Officer, President and Director
Stuart Shanler - Co-Founder and Chief Scientific Officer
Jeff Wayne - Interim Chief Commercial Officer
Frank Ruffo - Co-Founder and Chief Financial Officer
David Gordon - Chief Medical Officer

Conference Call Participants

Blair Cohen - Guggenheim Securities
Timothy Lugo - William Blair

Operator

Good day, ladies and gentlemen, and welcome to the Aclaris Therapeutics Fourth Quarter 2018 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Kamil Ali-Jackson, Chief Legal Officer. Ma'am, you may begin.

Kamil Ali-Jackson

Thank you. I'm Kamil Ali-Jackson, Chief Legal Officer for Aclaris. Please note that earlier today, Aclaris issued it's press release announcing fourth quarter and full year 2018 results. For those of you who have not yet seen it, you will find the release posted in the Investors section of our website at www.aclaristx.com.

Joining me today for the call are Dr. Neal Walker, President and Chief Executive Officer; Dr. Stuart Shanler, our Chief Scientific Officer; Frank Ruffo, our Chief Financial Officer; David Gordon, our Chief Medical Officer; and Jeff Wayne, our Interim Head of Commercial Officer.

Before we begin our prepared remarks, I would like to remind you that various statements we make during this call about the company's future results of operations and financial position, business strategy and plans and objectives for Aclaris' future operations are considered forward-looking statements within the meaning of the federal securities laws. Our forward-looking statements are based upon current expectations and involve risks, changes in circumstances, assumptions and uncertainties that could cause actual results to differ materially from those reflected in such statements. These risks